Opeyimi Olabisi

Opeyemi Olabisi is a physician-scientist and assistant professor of medicine at Duke School of Medicine. He practices adult nephrology and conducts NIH-funded research that leverages patient-derived stem cell models to elucidate mechanisms underlying APOL1 nephropathy. He is a recipient of several awards, including the NIH Director’s New Innovator Award, Duke Whitehead Scholars award, and the Albert Einstein College of Medicine Alumni’s Rising Star–Scientific Investigator Award. Dr. Olabisi received his bachelor’s degree in biology from The City College of New York and his MD-PhD from Albert Einstein College of Medicine. He completed both his residency training in internal medicine and his nephrology fellowship at Massachusetts General Hospital (MGH), and did a postdoctoral research fellowship at Harvard Medical School.

Education and Training

• Fellowship, Nephrology, Massachusetts General Hospital, 2012 - 2015
• Residency, Internal Medicine, Massachusetts General Hospital, 2010 - 2012
• Ph.D., Yeshiva University, Albert Einstein College of Medicine, 2009
• M.D., Yeshiva University, Albert Einstein College of Medicine, 2009

Grants

• JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
• A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX¿147 in Adults With APOL1-dependent Focal Segmental Glomerulosclerosis
• A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
• A Human Stem Cell-Derived Podocyte Model for APOL1 Nephropathy
• Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE III) ("Study")
• Duke Training Grant in Nephrology
• Icagen SRA

PUBLICATIONS

• DeOliveira, Margaret, Colby Feeney, Caroline Leahy, Sarah Nystrom, David N. Howell, Samira S. Farouk, Ming Wu, Opeyemi A. Olabisi, and Matthew A. Sparks. “Collapsing Glomerulopathy in Identical Twins With Lupus and High-Risk Apolipoprotein L1 (APOL1) Genotype.” Kidney International Reports 6, no. 9 (September 2021): 2501–4. https://doi.org/10.1016/j.ekir.2021.06.005.

• Olabisi, Opeyemi A., and Barry I. Freedman. “APOL1-associated kidney disease in northern Nigerians with treated HIV infection.” Kidney International 100, no. 1 (July 2021): 19–21. https://doi.org/10.1016/j.kint.2021.04.023.

• Freedman, Barry I., Wylie Burke, Jasmin Divers, Lucy Eberhard, Crystal A. Gadegbeku, Rasheed Gbadegesin, Michael E. Hall, et al. “Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review.” J Am Soc Nephrol, April 14, 2021. https://doi.org/10.1681/ASN.2020101399.

• Datta, Somenath, Rama Kataria, Jia-Yue Zhang, Savannah Moore, Kaitlyn Petitpas, Adam Mohamed, Nathan Zahler, Martin R. Pollak, and Opeyemi A. Olabisi. “Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.” Journal of the American Society of Nephrology : Jasn 31, no. 9 (September 2020): 2083–96. https://doi.org/10.1681/asn.2020010079.

• Norris, Keith C., Opeyemi Olabisi, M Edwina Barnett, Yuan-Xiang Meng, David Martins, Chamberlain Obialo, Jae Eun Lee, and Susanne B. Nicholas. “The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease.” International Journal of Environmental Research and Public Health 15, no. 12 (November 30, 2018). https://doi.org/10.3390/ijerph15122701.

• Olabisi, Opeyemi A., and John F. Heneghan. “APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?” Seminars in Nephrology 37, no. 6 (November 2017): 546–51. https://doi.org/10.1016/j.semnephrol.2017.07.008.

• Olabisi, Opeyemi A., Jia-Yue Zhang, Lynn VerPlank, Nathan Zahler, Salvatore DiBartolo, John F. Heneghan, Johannes S. Schlöndorff, et al. “APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.” Proceedings of the National Academy of Sciences of the United States of America 113, no. 4 (January 2016): 830–37. https://doi.org/10.1073/pnas.1522913113.

• Olabisi, O., and J. V. Bonventre. “Acute kidney injury in cancer patients.” In Onconephrology: Cancer, Chemotherapy and the Kidney, 1–24, 2015. https://doi.org/10.1007/978-1-4939-2659-6_1.

• Suk, Hee Yun, Chen Zhou, Teddy T. C. Yang, Hong Zhu, Raymond Y. L. Yu, Opeyemi Olabisi, XiaoYong Yang, et al. “Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases.” J Biol Chem 288, no. 5 (February 1, 2013): 3477–88. https://doi.org/10.1074/jbc.M112.419150.

• Olabisi, Opeyemi A., and Chi-Wing Chow. “Assay for protein modification by poly-ADP-ribose in vitro.” Methods Mol Biol 780 (2011): 47–55. https://doi.org/10.1007/978-1-61779-270-0_3.

• Zhu, Hong, Hee Yun Suk, Raymond Y. L. Yu, Deborah Brancho, Opeyemi Olabisi, Teddy T. C. Yang, XiaoYong Yang, et al. “Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.” Mol Cell Biol 30, no. 18 (September 2010): 4379–90. https://doi.org/10.1128/MCB.01193-09.

• Olabisi, Opeyemi A., Noemi Soto-Nieves, Edward Nieves, Teddy T. C. Yang, Xiaoyong Yang, Raymond Y. L. Yu, Hee Yun Suk, Fernando Macian, and Chi-Wing Chow. “Regulation of transcription factor NFAT by ADP-ribosylation.” Molecular and Cellular Biology 28, no. 9 (May 2008): 2860–71. https://doi.org/10.1128/mcb.01746-07.

• Yang, Teddy T. C., Hee Yun Suk, Xiaoyong Yang, Opeyemi Olabisi, Raymond Y. L. Yu, Jorge Durand, Linda A. Jelicks, et al. “Role of transcription factor NFAT in glucose and insulin homeostasis.” Mol Cell Biol 26, no. 20 (October 2006): 7372–87. https://doi.org/10.1128/MCB.00580-06.

• Broderick, Patricia A., Opeyemi A. Olabisi, David N. Rahni, and Yueping Zhou. “Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.” Prog Neuropsychopharmacol Biol Psychiatry 28, no. 3 (May 2004): 547–57. https://doi.org/10.1016/j.pnpbp.2004.01.007.

• Olabisi, Opeyemi, Khaldoun Al-Romaih, Joel Henderson, Ritu Tomar, Iain Drummond, Calum MacRae, and Martin Pollak. “From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?” Clin Nephrol 86 (2016), no. 13 (n.d.): 114–18. https://doi.org/10.5414/CNP86S116.